Description
PrymaLab · Research Use Only
BPC 157 5mg + TB500 5mg
Half of a combination nobody has characterised · Which is the right amount to buy
A bpc-157 5mg tb-500 5mg vial is the smaller of two fills of a combination that has not been characterised in the published record. That is not a criticism of the article. It is the fact that should decide how much of it to buy, and it points at the smaller vial for a reason that has nothing to do with consumption rate or stability.
Specification Table
| Property | Value |
|---|---|
| Product format | Lyophilised powder, single vial, two components |
| Component 1 | BPC-157, 5 mg · 1419.5 g/mol · approximately 3.5 µmol |
| Component 2 | TB-500, 5 mg · mass depends on which article the name covers |
| Total stated content | 10 mg |
| Mass ratio | 1 to 1 |
| Molar ratio | Not calculable. The TB-500 designation covers articles differing several-fold in mass |
| BPC-157 sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Aromatic residues in BPC-157 | None. It cannot be quantified by 280 nm absorbance |
| Published work on this combination | None identified at this or any ratio |
| Published work on each component separately | Substantial for both, cited below |
| What that implies for design | A combination arm needs single-component arms alongside it |
| Storage, lyophilised | -20°C, sealed, dark and dry |
| Storage, reconstituted | 2-8°C, prepared fresh |
| Regulatory status | No approved human or veterinary formulation is supplied here |
Why Should Evidence Decide Whether to Buy BPC-157 5mg TB-500 5mg?
Because a purchase is a bet on how much of something gets used, and consumption depends on whether the thing works.
For a compound with a settled literature, that bet is easy. You know roughly what concentrations are involved and roughly what the material does, so consumption is predictable and buying to cover it is sensible.
For a combination nobody has published on, the first experiment is a question rather than a step in a programme.
Buying the larger fill commits money to an answer nobody has yet. The money does not make it arrive sooner.
So the smaller fill is the size that matches the state of the evidence, and this is the only page in this catalogue where I would put that argument first.
What Is Actually Published?
A great deal on each component of bpc-157 5mg tb-500 5mg separately, and nothing on the two together.
BPC-157 has a body of work largely from one research group, reviewed in Current Pharmaceutical Design and cited below. The 10mg page in this catalogue discusses what that record does and does not cover.
Thymosin beta-4, which is what TB-500 usually refers to or derives from, has a separate and larger literature on actin sequestration and tissue responses.
What I have not found is work characterising the two administered together, at any ratio, in any model.
That absence is the basis of this page, and precision about what it means matters here. It does not mean the combination does nothing. It means nobody has reported what it does.
Presenting the sum of two separate literatures as though it described the mixture is the move every competitor listing makes, and it does not follow.
One clarification about what I searched for and did not find.
I looked for work naming both compounds together in a single experimental design. What exists instead is a large number of listings, forum posts and marketing pages that assert the combination is superior, none of which cites anything.
That distinction matters. An absence of published work is not the same as an absence of claims, and this compound pair has plenty of the second kind.
What Would a Study Actually Need?
Four arms, and this vial gives you one of them.
A combination arm, a BPC-157 alone arm, a TB-500 alone arm, and a vehicle control.
Without the single-component arms there is no way to tell whether an effect is additive, synergistic, or entirely attributable to one of the two.
That means buying the single-component vials as well, which are both available separately here, and it means the blend is one line item in a design rather than the whole purchase.
It also means the blend has to be used at a ratio the single-component arms can match, and the fixed one-to-one mass ratio in this vial constrains that.
None of this is exotic. It is ordinary combination study design, and it is the reason a blend vial is a convenience rather than a shortcut.
A note on the ratio, because the four-arm design has a constraint the vial imposes.
The single-component arms have to run at the same concentrations the combination arm delivers. So the blend fixes what the controls must be, rather than the other way round.
Working that out means knowing the molar content of both components, and the section below explains why one of those numbers is not available.
Which is circular, and the way out is the certificate rather than the arithmetic.
Ask the supplier which article the TB-500 designation covers before designing anything around this vial. If they cannot say, the four-arm design cannot be specified properly, and buying the two components separately is the honest response.
That costs more and it produces a study somebody can replicate.
Why Is the Molar Ratio Not Stated?
Because one of the two components in bpc-157 5mg tb-500 5mg does not have a settled mass.
BPC-157 is a defined fifteen residue sequence weighing 1419.5, so five milligrams is about 3.5 micromoles and that figure is solid.
TB-500 is a trade designation rather than a chemical name, and it covers at least two different articles whose masses differ by more than a factor of five. The 5mg page for that compound in this catalogue sets the problem out in full.
So five milligrams of TB-500 is somewhere between about one micromole and about five and a half, and nothing on the label narrows it.
So a one-to-one mass ratio maps to a molar ratio somewhere between 1 to 0.3 and 1 to 1.6.
That range is unusable for stoichiometry. One line on the certificate would fix it.
What Can Be Said About the Components?
That the two are chemically unrelated and fail in different ways, which matters a good deal before they share a vial.
BPC-157 is proline-rich, three of them consecutive near the N terminus, and carries no aromatic residue anywhere in its fifteen positions. So it is hard to quantify by absorbance and hard to chromatograph cleanly. The 10mg page covers both.
Thymosin beta-4 is far longer, acetylated at the N terminus, with a well described actin binding motif.
Sharing a vial means sharing a storage temperature, a reconstitution event and a solution age, and the shorter of the two stability clocks governs.
I have not found stability data for either component in this specific co-formulation, so which clock is shorter is an inference from the components rather than a measurement.
What Should the Certificate Show?
A bpc-157 5mg tb-500 5mg certificate needs purity per component rather than one figure for the vial.
Measured content of each component against label, because a blend certificate that reports only a total has not answered the question anybody has.
Which article the TB-500 designation refers to, stated as a sequence or a molecular weight rather than as a trade name.
The BPC-157 sequence written out.
The method used to apportion the two, which on a blend with no shared chromophore is not trivial.
Lot number and manufacturing date.
What Would Change the Recommendation?
Published work on the bpc-157 5mg tb-500 5mg combination, and that is the whole list.
If a paper appeared characterising these two together at a defined ratio in a defined model, the calculation changes immediately: consumption becomes predictable, the ratio becomes justifiable, and buying to cover a programme becomes sensible.
Until then, every purchase of this blend is a first experiment, and first experiments should be sized like first experiments.
I would also change position if a supplier resolved the TB-500 identity question on the certificate, because half the reason the molar ratio is unusable is that nobody says which article the name covers.
Neither of those is in my gift. Both are worth asking about.
Why Does This Blend Exist?
Because people ask for it.
The combination has a following that predates any evidence, built on forum discussion and on the reasonable-sounding idea that two compounds associated with tissue responses ought to work better together than either alone.
That idea might be right.
What it is not is established, and the gap between a plausible mechanism and a demonstrated effect is where most of this market operates, so a page that says the gap exists is doing something the listings around it are not.
The vial is not the problem.
A co-formulation at a fixed ratio is a perfectly reasonable thing to sell, and for a laboratory running the combination arm of a properly controlled study it is a convenience worth paying for.
The problem is the framing.
Sold as a shortcut it is misleading, and sold as one line item in a four-arm design it is exactly what it looks like, which is two compounds in a vial at a ratio somebody chose for the packaging.
How Should the Vial Be Handled?
Handle bpc-157 5mg tb-500 5mg to whichever component is fussier, and prepare solutions fresh because you do not know which that is.
Sealed at minus 20 degrees Celsius, dark and dry.
Room temperature before opening, then diluent down the wall and gentle rotation rather than shaking.
Aliquot into single-use volumes and refrigerate. Do not hold a made-up solution for weeks on the assumption that both components tolerate it.
The smaller fill genuinely helps here, and it is the second honest argument for it: less material means the vial finishes sooner and less time passes with an uncharacterised mixture sitting in water.
Ordinary low-binding precautions apply to both components at the dilute end of a series.
Published Literature
Full citations for the work named above, each confirmed against the publisher record. None of it describes the two components in combination, which is stated on the page rather than left for the reader to notice.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Current Pharmaceutical Design. 2011;17(16):1612-1632. DOI: 10.2174/138161211796196954
- Safer D, Elzinga M, Nachmias VT. Journal of Biological Chemistry. 1991;266(7):4029-4032. PMID: 1999384
- Goldstein AL, Hannappel E, Kleinman HK. Trends in Molecular Medicine. 2005;11(9):421-429. DOI: 10.1016/j.molmed.2005.07.004
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Pharmaceutical Research. 2010;27(4):544-575. DOI: 10.1007/s11095-009-0045-6
Frequently Asked Questions
What is in a BPC-157 5mg plus TB-500 5mg vial?
Five milligrams each of BPC-157 and TB-500, co-lyophilised in one vial for a stated total of ten milligrams. It is the smaller of two fills of this blend and it is supplied for laboratory research only.
Is this combination published?
Not that I can find. Both components have separate literatures, substantial in both cases, and I have found no work characterising the two together at any ratio in any model. That absence does not mean the combination does nothing, only that nobody has reported what it does.
Why does that argue for the smaller fill?
Because the first experiment on an uncharacterised combination is a question rather than a step in a programme. Buying the larger fill commits money to an answer you do not have, and it does not make the answer arrive sooner.
What would a proper study design look like?
Four arms: the combination, BPC-157 alone, TB-500 alone, and a vehicle control. Without the single-component arms there is no way to attribute an effect to either component or to the combination.
Why is the molar ratio not stated?
Because TB-500 is a trade designation rather than a chemical name and covers articles differing more than fivefold in mass. Five milligrams of it is somewhere between about one and five and a half micromoles, so a one to one mass ratio maps to a wide molar range.
How many micromoles of BPC-157 are in the vial?
About 3.5, at a molecular weight of 1419.5 for the fifteen residue sequence. That figure is solid. The TB-500 side is not.
Can I quantify BPC-157 by absorbance?
No. Its sequence contains no tryptophan, tyrosine or cystine, so it has no chromophore at 280 nanometres. The 10mg page for that compound covers the quantification problem that follows.
Which component limits the solution life?
Unknown for this co-formulation. I have found no stability data for either component in this specific mixture, so prepare solutions fresh rather than reasoning from either component alone.
What should a blend certificate show?
Purity per component, measured content of each against label, which article the TB-500 designation refers to stated as a sequence or molecular weight, the BPC-157 sequence written out, the method used to apportion the two, and lot details.
Should I buy the blend or the two components separately?
Separately if the study needs single-component arms, which any honest combination design does. The blend is a convenience for the combination arm rather than a substitute for the other three.
How should the vial be stored?
Sealed at minus 20 degrees Celsius, dark and dry. Reconstituted solution at 2 to 8 degrees, prepared fresh rather than held, because the shorter of two unmeasured stability clocks governs.
Is this product for human use?
No. Research material for a laboratory, and nothing else. It is not a drug, food, cosmetic or dietary product, the FDA has never evaluated it, and it must not reach a person or an animal.
Compliance Statement
This BPC-157 and TB-500 blend is supplied exclusively for laboratory research use. It is not a drug, food, cosmetic or dietary product of any kind. It has not been evaluated by the FDA or any comparable authority, and no approved human or veterinary formulation is supplied here. It is not intended to diagnose, treat, cure or prevent any disease, and it must not be given to humans or animals. No published work characterising this combination was identified, and nothing on this page should be read as a claim about the mixture derived from work on its individual components. Purchase is restricted to qualified researchers and institutions.
Other formats of BPC 157 + TB500
BPC 157 + TB500 is also stocked as Wolverine Stack (BPC-157 + TB-500) 20mg preloaded 3ml pen, BPC-157 + TB500 (10mg/10mg) "Wolverine Blend", BPC-157 5MG, BPC-157 10MG, BPC-157 Capsules (60/500mcg), BPC-157 Peptide Nasal Spray, BPC-157 5mg/ml preloaded 3ml pen and TB-500 5mg/ml preloaded 3ml pen. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
22 reviews for BPC 157 5mg + TB500 5mg